Biking might help lower risk of dementia
Get on your bike and ride, a new study recommends.
Biking regularly for transportation appears to lower risk of dementia by 19% and Alzheimer's by 22%, according to results published Tuesday in JAMA Network Open.
The results also suggest that cycling might even help increase the size of a brain region important for memory, researchers noted.
"Cycling is a moderate- to high-intensity workout, and also requires balance," said Dr. Liron Sinvani, director of geriatric services at Northwell Health in Manhasset, N.Y., who reviewed the findings. "It requires more complex brain function than walking, which is why maybe it was a better reducer of dementia risk."
"It's not about just doing exercise and making that part of your routine, but thinking about the way you live your life," she added in a news release. "So instead of having to drive somewhere, taking that bike and using active travel modes to get around as part of your lifestyle becomes very important."
For the study, researchers analyzed data on nearly 480,000 people participating in the UK Biobank, a long-term health study of people living in England, Scotland and Wales.
As part of the study, participants noted the forms of transport they used most often to get about, not including travel to and from work.
During an average follow-up of 13 years, more than 8,800 participants developed dementia and nearly 4,000 developed Alzheimer's.
Results showed a lower risk for dementia and Alzheimer's among those who cycled or included cycling among other forms of travel like walking, driving or using public transportation.
"Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," concluded the research team led by Liangkai Chen, an associate professor at Tongji Medical College at the Huazhong University of Science and Technology in Wuhan, China.
MRI brain scans showed that cycling also was associated with a larger hippocampus, a part of the brain involved in memory formation and learning, researchers noted.
However, cycling's benefits appeared to extend mostly to people without a genetic risk for Alzheimer's, results showed.
People without the APOE E4 genetic variant had a 26% lower risk of dementia and 25% lower risk of Alzheimer's.
Results were not statistically significant among APOE E4 carriers, but indicated less protection from cycling.
Interestingly, the results also indicate that driving offered some protection against dementia compared to taking the bus or subway.
"Even when using inactive travel like car or public transportation, it seemed like driving had a little bit better impact [on brain health] than public transportation," Sinvani said in the news release.
However, researchers noted that this observational study could not draw a direct cause-and-effect link between cycling and healthy brain aging.
"What I tell my patients and family and friends whenever they ask me what they can do to reduce their risk of dementia, is whatever gets you outside doing stuff is what you should be doing," she said. "I think we see that it's not just the physical activity, but it's also in the balance, and it really engages different parts of your brain."
If you're able to get on a bike, Sinvani said, do that. If you're aren't, use your feet.
"I think if it's, 'should I walk or take a bike?' I would say take a bike, but if it's 'should I walk or just stay home?' I would say definitely walk," she said.
More information
The U.S. Centers for Disease Control and Prevention has more on how physical activity boosts brain health.
Copyright © 2025 HealthDay. All rights reserved.
Copyright 2025 UPI News Corporation. All Rights Reserved.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
4 hours ago
- Politico
Supreme Court lets Trump admin cut off health grants it says advance DEI or ‘gender ideology extremism'
Chief Justice John Roberts joined the court's liberals in dissent from the court's decision to permit the funding halt. The Supreme Court is allowing the Trump administration to cut off health research grants it contends advance diversity, equity and inclusion efforts or promote 'gender ideology extremism.' By a 5-4 vote, the justices lifted an order a federal court judge in Boston issued forcing the National Institutes of Health to restore funding for more than 1,700 grants focused on heart disease, HIV/AIDS, Alzheimer's disease, alcohol and substance abuse and mental health issues. Chief Justice John Roberts joined the court's liberals in dissent from the court's decision to permit the funding halt.
Yahoo
4 hours ago
- Yahoo
Supreme Court lets Trump admin cut off health grants it says advance DEI or ‘gender ideology extremism'
The Supreme Court is allowing the Trump administration to cut off health research grants it contends advance diversity, equity and inclusion efforts or promote 'gender ideology extremism.' By a 5-4 vote, the justices lifted an order a federal court judge in Boston issued forcing the National Institutes of Health to restore funding for more than 1,700 grants focused on heart disease, HIV/AIDS, Alzheimer's disease, alcohol and substance abuse and mental health issues. Chief Justice John Roberts joined the court's liberals in dissent from the court's decision to permit the funding halt. While Barrett voted with most of the court's conservatives to let the administration stop the grant funding, she sided with Roberts and the liberals to form a majority that left in place the lower judge's order voiding several NIH policies aimed at enforcing Trump's anti-DEI edicts. Since the ruling leaves the grant recipients without federal funds for now, the Trump administration seems certain to claim it as yet another in a flurry of wins in emergency appeals it has filed with the Supreme Court. In a solo concurring opinion, Barrett indicated that the court's ruling Thursday signaled that the grant recipients should have brought their claims for lost funding not to a district judge in Boston but to the U.S. Court of Federal Claims in Washington, which hears disputes over federal contracts. U.S. District Judge William Young ordered the health-related grants restored in June, following lawsuits filed by impacted grant recipients and 16 Democratic-led states complaining of cuts to programs at their state universities. Young, a Reagan appointee, used unusually strident language to condemn the targeted cuts, many of which ended grants studying the impacts of disease on specific minority groups. 'This represents racial discrimination and discrimination against America's LGBTQ community,' the judge said of the cuts. 'I would be blind not to call it out. My duty is to call it out.' However, in Thursday's ruling, Justice Neil Gorsuch accused Young of defying the Supreme Court by not abiding by an emergency ruling it issued in April, allowing the Trump administration to cancel $64 million in teaching-related grants. (That 5-4 ruling also found Roberts in dissent along with the three liberal justices.) 'When this Court issues a decision, it constitutes a precedent that commands respect in lower courts,' Gorsuch declared, joined by Justice Brett Kavanaugh. Justice Ketanji Brown Jackson penned a blistering 21-page solo opinion calling the court's latest ruling 'bizarre' and complaining in particular about her colleagues 'sending plaintiffs on a likely futile, multivenue quest for complete relief.' She even declared that the court's decision will result in animals used in medical experiments being 'euthanized.' Jackson also repeated her past assertions that the high court is bending over backward to favor the Trump administration. 'Calvinball has only one rule: There are no fixed rules. We seem to have two: that one, and this Administration always wins,' she wrote. In filings with the high court over the NIH funding, the Trump administration complained that Young's order required the agency to 'pay out over $783 million in grants,' but grant recipients argued that 'figure appears to be invented out of whole cloth.' Solicitor General John Sauer ridiculed some of the grants shut down by the administration, pointing to funding for programs exploring 'intersectional, multilevel and multidimensional structural racism for English- and Spanish-speaking populations' and 'anti-racist healing in nature.' Sauer told the justices that a 'comprehensive internal review' found the grants ran afoul of one or more of three executive orders President Donald Trump issued shortly after he returned to office in January. Two of the directives targeted DEI-related programs and grants, while the third sought to affirm 'the immutable biological reality of sex' by ending policies and programs accommodating or benefiting transgender people. Sauer also put forward the argument that appeared to carry the day Thursday: Congress has mandated legal disputes over federal government grants and contracts be pursued only in the Court of Federal Claims. That court could eventually award financial damages to grantees if it determines their grants were illegally terminated, but is unlikely to provide immediate relief, according to legal experts. The Supreme Court's ruling on the NIH grants is not a final decision on the legality of the grant terminations. But it means the administration can withhold the funding while the legal fight plays out. The Trump administration has appealed Young's ruling to the 1st Circuit Court of Appeals, which last month declined the administration's request to put his decision on hold as the appeal proceeds.
Yahoo
5 hours ago
- Yahoo
PET imaging gains momentum while SPECT maintains strength in nuclear medicine
Nuclear imaging is entering a period of notable change. Positron emission tomography (PET) scans are gaining traction in oncology and other high-value applications, driven by innovations in tracer development, theranostics, and advanced imaging technologies. According to leading data and analytics company GlobalData's market analysis, the global PET imaging agent market is valued at $2.1bn in 2025, compared to $4.7bn for single-photon emission computed tomography (SPECT). Between 2025 and 2035, PET agents are projected to grow at a compound annual growth rate of 4.6% in market value and 4.7% in procedure volume, a rate 5.5 times higher than the projected growth of SPECT agents. PET growth is primarily driven by tracer innovation, with recent successes in prostate-specific membrane antigen-based scans and clinical fibroblast activation protein inhibitors demonstrating how PET can directly influence treatment decisions. Advanced PET imaging in Alzheimer's disease also holds promise for improving early detection and monitoring of disease progression. The rise of theranostics, which integrate diagnostic PET tracers with therapeutic radioligands, strengthens the PET value proposition by linking imaging with treatment. Emerging tools such as AI-based image quantification and standardised reporting are also expected to improve scan consistency and reduce variability in interpretation, further increasing PET's role in advanced clinical care. These capabilities are encouraging broader adoption of PET across both diagnosis and therapy planning. Comparatively, SPECT remains a key modality in nuclear medicine, supported by established supply chains, low equipment costs, and a longstanding use in cardiology and general nuclear medicine. Technetium-based SPECT scans account for the majority of nuclear medicine procedures worldwide, estimated at 76% in 2025 and projected to hold strong at 70% in 2035. In many regions, particularly those with limited infrastructure, SPECT will remain the practical and reliable choice. Looking ahead, the nuclear imaging market pipeline reflects this shift towards PET usage and development. GlobalData's Pipeline Products Database tracks 129 PET agents in active development compared to 14 for SPECT. Among these, one SPECT agent and seven PET agents are in the approval process and are likely to launch in 2025-26. PET adoption is accelerating, particularly in high-income markets, and is poised to capture a growing share of the global nuclear imaging market, especially in high-value applications. Meanwhile, SPECT will continue to provide accessible and reliable coverage in routine clinical practice. Companies that focus on diversifying tracers, securing supply chains, and aligning strategies with regional infrastructure needs are likely to be best positioned to capitalise on this ongoing transition. Challenges, including radioisotope supply fluctuations, training demands, and variations in global access may influence adoption across specific markets. "PET imaging gains momentum while SPECT maintains strength in nuclear medicine" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio